vs
迈心诺（MASI）与TransMedics Group, Inc.（TMDX）财务数据对比。点击上方公司名可切换其他公司
迈心诺的季度营收约是TransMedics Group, Inc.的2.3倍（$371.5M vs $160.8M）。TransMedics Group, Inc.净利率更高（65.6% vs -27.0%，领先92.6%）。TransMedics Group, Inc.同比增速更快（32.2% vs -26.4%）。迈心诺自由现金流更多（$50.9M vs $19.0M）。过去两年TransMedics Group, Inc.的营收复合增速更高（28.8% vs -17.7%）
迈心诺（Masimo Corporation）是总部位于美国加利福尼亚州尔湾的健康科技及消费电子企业，核心产品包括面向医院及家用场景的患者监护设备、无创传感器及配套软件平台，同时也布局了消费级音频和可穿戴设备赛道。
TransMedics Group, Inc.是一家专注于器官移植领域的医疗科技企业，核心产品器官护理系统可在运输过程中维持捐献器官的活性，提升心、肺、肝、肾移植手术的成功率，服务覆盖北美、欧洲及亚太地区的移植中心与器官获取组织。
MASI vs TMDX — 直观对比
营收规模更大
MASI
是对方的2.3倍
$160.8M
营收增速更快
TMDX
高出58.6%
-26.4%
净利率更高
TMDX
高出92.6%
-27.0%
自由现金流更多
MASI
多$31.9M
$19.0M
两年增速更快
TMDX
近两年复合增速
-17.7%
损益表 — Q3 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $371.5M | $160.8M |
| 净利润 | $-100.4M | $105.4M |
| 毛利率 | 62.1% | 58.1% |
| 营业利润率 | 22.5% | 13.2% |
| 净利率 | -27.0% | 65.6% |
| 营收同比 | -26.4% | 32.2% |
| 净利润同比 | -1124.5% | 1436.9% |
| 每股收益（稀释后） | $-1.84 | $2.59 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MASITMDX
| Q4 25 | — | $160.8M | ||
| Q3 25 | $371.5M | $143.8M | ||
| Q2 25 | $370.9M | $157.4M | ||
| Q1 25 | $372.0M | $143.5M | ||
| Q4 24 | $600.7M | $121.6M | ||
| Q3 24 | $504.6M | $108.8M | ||
| Q2 24 | $496.3M | $114.3M | ||
| Q1 24 | $492.8M | $96.8M |
净利润MASITMDX
| Q4 25 | — | $105.4M | ||
| Q3 25 | $-100.4M | $24.3M | ||
| Q2 25 | $51.3M | $34.9M | ||
| Q1 25 | $-170.7M | $25.7M | ||
| Q4 24 | $-349.6M | $6.9M | ||
| Q3 24 | $9.8M | $4.2M | ||
| Q2 24 | $16.0M | $12.2M | ||
| Q1 24 | $18.9M | $12.2M |
毛利率MASITMDX
| Q4 25 | — | 58.1% | ||
| Q3 25 | 62.1% | 58.8% | ||
| Q2 25 | 62.9% | 61.4% | ||
| Q1 25 | 62.9% | 61.5% | ||
| Q4 24 | 40.7% | 59.2% | ||
| Q3 24 | 52.2% | 55.9% | ||
| Q2 24 | 51.3% | 60.6% | ||
| Q1 24 | 49.0% | 61.9% |
营业利润率MASITMDX
| Q4 25 | — | 13.2% | ||
| Q3 25 | 22.5% | 16.2% | ||
| Q2 25 | 17.4% | 23.2% | ||
| Q1 25 | 21.0% | 19.1% | ||
| Q4 24 | -59.8% | 7.1% | ||
| Q3 24 | 6.0% | 3.6% | ||
| Q2 24 | 5.7% | 10.9% | ||
| Q1 24 | 6.9% | 12.8% |
净利率MASITMDX
| Q4 25 | — | 65.6% | ||
| Q3 25 | -27.0% | 16.9% | ||
| Q2 25 | 13.8% | 22.2% | ||
| Q1 25 | -45.9% | 17.9% | ||
| Q4 24 | -58.2% | 5.6% | ||
| Q3 24 | 1.9% | 3.9% | ||
| Q2 24 | 3.2% | 10.7% | ||
| Q1 24 | 3.8% | 12.6% |
每股收益（稀释后）MASITMDX
| Q4 25 | — | $2.59 | ||
| Q3 25 | $-1.84 | $0.66 | ||
| Q2 25 | $0.94 | $0.92 | ||
| Q1 25 | $-3.12 | $0.70 | ||
| Q4 24 | $-6.54 | $0.19 | ||
| Q3 24 | $0.18 | $0.12 | ||
| Q2 24 | $0.29 | $0.35 | ||
| Q1 24 | $0.35 | $0.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $312.3M | — |
| 总债务越低越好 | $559.1M | — |
| 股东权益账面价值 | $810.0M | $473.1M |
| 总资产 | $1.8B | $1.1B |
| 负债/权益比越低杠杆越低 | 0.69× | — |
8季度趋势，按日历期对齐
现金及短期投资MASITMDX
| Q4 25 | — | — | ||
| Q3 25 | $312.3M | — | ||
| Q2 25 | $149.6M | — | ||
| Q1 25 | $130.8M | — | ||
| Q4 24 | $177.6M | — | ||
| Q3 24 | $158.5M | $330.1M | ||
| Q2 24 | $129.6M | $362.8M | ||
| Q1 24 | $157.6M | $350.2M |
总债务MASITMDX
| Q4 25 | — | — | ||
| Q3 25 | $559.1M | — | ||
| Q2 25 | $613.7M | — | ||
| Q1 25 | $651.0M | — | ||
| Q4 24 | $765.2M | — | ||
| Q3 24 | $772.6M | — | ||
| Q2 24 | $781.6M | — | ||
| Q1 24 | $876.0M | — |
股东权益MASITMDX
| Q4 25 | — | $473.1M | ||
| Q3 25 | $810.0M | $355.2M | ||
| Q2 25 | $1.0B | $318.1M | ||
| Q1 25 | $946.4M | $266.3M | ||
| Q4 24 | $1.1B | $228.6M | ||
| Q3 24 | $1.5B | $209.9M | ||
| Q2 24 | $1.4B | $189.9M | ||
| Q1 24 | $1.4B | $159.5M |
总资产MASITMDX
| Q4 25 | — | $1.1B | ||
| Q3 25 | $1.8B | $946.0M | ||
| Q2 25 | $2.4B | $890.5M | ||
| Q1 25 | $2.3B | $837.5M | ||
| Q4 24 | $2.6B | $804.1M | ||
| Q3 24 | $3.1B | $785.6M | ||
| Q2 24 | $2.9B | $758.6M | ||
| Q1 24 | $3.0B | $723.8M |
负债/权益比MASITMDX
| Q4 25 | — | — | ||
| Q3 25 | 0.69× | — | ||
| Q2 25 | 0.59× | — | ||
| Q1 25 | 0.69× | — | ||
| Q4 24 | 0.73× | — | ||
| Q3 24 | 0.53× | — | ||
| Q2 24 | 0.57× | — | ||
| Q1 24 | 0.64× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $56.8M | $34.5M |
| 自由现金流经营现金流 - 资本支出 | $50.9M | $19.0M |
| 自由现金流率自由现金流/营收 | 13.7% | 11.8% |
| 资本支出强度资本支出/营收 | 1.6% | 9.7% |
| 现金转化率经营现金流/净利润 | — | 0.33× |
| 过去12个月自由现金流最近4个季度 | $191.0M | $133.6M |
8季度趋势，按日历期对齐
经营现金流MASITMDX
| Q4 25 | — | $34.5M | ||
| Q3 25 | $56.8M | $69.6M | ||
| Q2 25 | $69.4M | $91.6M | ||
| Q1 25 | $31.1M | $-2.9M | ||
| Q4 24 | $50.5M | $19.7M | ||
| Q3 24 | $25.6M | $6.9M | ||
| Q2 24 | $74.5M | $25.7M | ||
| Q1 24 | $45.8M | $-3.4M |
自由现金流MASITMDX
| Q4 25 | — | $19.0M | ||
| Q3 25 | $50.9M | $61.9M | ||
| Q2 25 | $65.6M | $82.5M | ||
| Q1 25 | $28.5M | $-29.9M | ||
| Q4 24 | $46.0M | $6.1M | ||
| Q3 24 | $16.9M | $-41.3M | ||
| Q2 24 | $66.9M | $2.0M | ||
| Q1 24 | $37.6M | $-47.6M |
自由现金流率MASITMDX
| Q4 25 | — | 11.8% | ||
| Q3 25 | 13.7% | 43.1% | ||
| Q2 25 | 17.7% | 52.4% | ||
| Q1 25 | 7.7% | -20.8% | ||
| Q4 24 | 7.7% | 5.0% | ||
| Q3 24 | 3.3% | -38.0% | ||
| Q2 24 | 13.5% | 1.7% | ||
| Q1 24 | 7.6% | -49.2% |
资本支出强度MASITMDX
| Q4 25 | — | 9.7% | ||
| Q3 25 | 1.6% | 5.3% | ||
| Q2 25 | 1.0% | 5.8% | ||
| Q1 25 | 0.7% | 18.8% | ||
| Q4 24 | 0.7% | 11.2% | ||
| Q3 24 | 1.7% | 44.3% | ||
| Q2 24 | 1.5% | 20.8% | ||
| Q1 24 | 1.7% | 45.6% |
现金转化率MASITMDX
| Q4 25 | — | 0.33× | ||
| Q3 25 | — | 2.86× | ||
| Q2 25 | 1.35× | 2.62× | ||
| Q1 25 | — | -0.11× | ||
| Q4 24 | — | 2.87× | ||
| Q3 24 | 2.61× | 1.63× | ||
| Q2 24 | 4.66× | 2.11× | ||
| Q1 24 | 2.42× | -0.28× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MASI
暂无分部数据
TMDX
| Liver Product | $127.0M | 79% |
| Heart Product | $26.0M | 16% |
| Other | $5.9M | 4% |
| Lung Product | $1.9M | 1% |
